Abstract The sigma-1 receptor (s 1 R) is a unique intracellular protein. s 1 R plays a major role in various pathological conditions in the central nervous system (CNS), implicated in several neuropsychiatric disorders. Imaging of s 1 R in the brain using positron emission tomography (PET) could serve as a noninvasively tool for enhancing the understanding of the disease's pathophysiology. Moreover, s 1 R PET tracers can be used for target validation and quantification in diagnosis. Herein, we describe the radiosynthesis, in vivo PET/CT imaging of novel s 1 R 11 C-labeled radioligands based on 6-hydroxypyridazinone, . Two radioligands have high affinities to s 1 R, with good selectivity. In mice PET/CT imaging, both radioligands showed appropriate kinetics and distributions. Additionally, the specific interactions of two radioligands were reduced by compounds 13 and 15 (self-blocking). Of Abbreviations: 3D, three-dimensional; s 1 R, sigma-1 receptor; s 2 R, sigma-2 receptor; AF, ammonium formate; BBB, brain blood barrier; BP, binding potential; CNS, center nervous systems; CRPS, complex regional pain syndrome; DMF, dimethyl formamide; DMSO, dimethylsulfoxide; ER, endoplasmic reticulum; LCP, lipidic cubic phase; MAM, mitochondria-associated ER membrane; PCP, phencyclidine; PET, positron emission tomography; TFA, trifluoroacetic acid. 
Novel radioligands for imaging sigma-1 receptor in brain using positron emission tomography (PET) As an enigmatic intracellular protein, the history of sigma (s) receptor was originally categorized as an opioid receptor subtype 1 , and later confused with the phencyclidine (PCP) receptor due to the lack of selective ligands 2 . Subsequent pharmacological studies and molecular biology have finally identified that the s receptor is a non-opioid and non-PCP protein, which was at least two known subtypes, classified as sigma-1 (s 1 ) and sigma-2 (s 2 ) receptor. These two subtypes are pharmacologically similar but genetically unrelated, with different body distribution, biological function and pharmacological profiles 3e6 . At present, sigma-1 receptor (s 1 R) is known as a unique protein that shares no sequence homology with opioids or any other human proteins but is highly conserved across mammalian species. s 1 R is a 23.5 kDa that is 223 amino acids in length 5 . s 1 R is widely expressed in the central nervous system (CNS) and peripheral tissues and organs 7, 8 . Mainly residing in the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM) of cell, s 1 R has been reported to interacted with numerous neurotransmitter receptors and ion channels, involved in diverse basic biochemical processes and pathological conditions related to neurodegeneration, pain sensitization, psychiatric disorders, and drug addiction 7, 9, 10 . s 1 R is also found overexpressed in many known human cancers in lung, breast, prostate, and glioma cells 11, 12 . The first crystal structure of human s 1 R was recently solved using lipidic cubic phase (LCP) crystallography. The three-dimensional (3D) protein structure of human s 1 R receptor showed a membrane-bound trimeric assembly with one transmembrane region, modifying the previous hypothesis that the receptor had two transmembrane domains 13, 14 . Despite the fact that structural information has only recently become available, and no endogenous ligand has been established for the receptor, numerous small molecule ligands for s 1 R have been reported over the past few decades. Among these compounds, some have been developed as radiolabeled imaging tracers ( Fig. 1 ) for positron emission tomography (PET) applications 15e17 . As a translational noninvasive imaging method, PET imaging of s 1 R is a promising modality to evaluate distribution and expression in inaccessible regions and tissues. Additionally, with the specificity and selectivity radioligands, examining s 1 R through PET could facilitate the investigation of in vivo role in pathology and progression of s 1 R in different diseases directly 18 . Several radiolabeled s 1 R ligands have been studied in PET imaging of human investigation, but only a few of them have been used clinically. [ 11 C]SA 4503 (1) is the first s 1 R radioligand in human studies 18 . The ex vivo binding assays of SA 4503 was initially reported as nanomolar affinity of s 1 R (K i Z4.6 nmol/L) and highly selectivity to s 1 R (s 2 /s 1 Z103) 19 , later the selectivity to s 2 R was reinvestigated as 13.3e55.0 18, 20 . Besides, the low selectivity either to the emopamil binding protein (EBP) or to the vesicular acetylcholine transporter (VAChT) limited its broad use in clinic studies 19, 20 . 26, 27 , still each of them have unmet requirements and needs further investigation for practical clinic translation.
In our previous work, we identified 6-hydroxypyridazinone class of compounds with high s 1 R affinity and high selectivity over s 2 R 28 . Ex vivo tests suggested comp-54 (6) of 6-hydroxypyridazinone derivatives were reported as the most promising candidate of high binding affinity (s 1 R K i Z1.4 nmol/L) and apparent good selectivity (s 2 /s 1 Z1365.7). The pharmacological test of in vivo evaluation in rodent showed it was a s 1 R antagonist and could possibly penetrate the blood-brain barrier (BBB), and get into the s 1 R-expressed region in mice brain, which exerted a highly potency of modified into s 1 R radioligand for brain PET imaging. Aiming to preserve this high affinity and selectivity, we devised a strategy to modify 6 in ways that would incorporate a carbon-11 radiolabel without greatly altering the original framework of 6-hydroxypyridazinone in the target molecules.
To the best of our knowledge, no similar compounds with 6-hydroxypyridazinone scaffold have been developed as s 1 R PET radiotracer. Since the core structure is distinct from existing PET radioligands for s 1 R imaging, it could expand the diversity of available probes and facilitate future advances in a s 1 R imaging. Here, we report the radiosynthesis of two novel carbon-11-labeled s 1 R radioligands, [
11 C]HCC0923 and [ 11 C ]HCC0929, and demonstrate the in vivo pharmacokinetic properties, biodistribution of brain regions and major organs through PET/CT imaging for s 1 R in the mice.
Results and discussion

Chemical synthesis
The chemical synthesis of the compounds 13e15 was illustrated in Scheme 1. The 6-hydroxypyridazinone derivatives were prepared following our previously reported work with minor changes 28, 29 . Briefly, through a one-step cyclization reaction of substitute phenylhydrazine hydrochloride and maleic anhydride, the intermediates 9 and 10 were prepared as white solid; Next, standard alkylation with 1,3-dibromopropane in acetone using potassium carbonate (K 2 CO 3 ) was conducted to produce 11 and 12, and then reacted with the piperidine, tert-butyl piperazine-1-carboxylate or 1-methylpiperazine respectively in the presence of cesium carbonate (Cs 2 CO 3 ) in acetonitrile to afford the compound 13e15 in moderate yields. The preparation of the precursors P1 and P2 were using straightforward methods, as presented in Scheme 2. For precursor P1, the methoxy group in compound 13 was turned to hydroxy group by demethylation of BBr 3 in -78 C 30 . For precursor P2, the tert-butyl ester in compound 14 was hydrolyzed in the presence of HCl solution in diethyl ether (2 mol/L) to form the designed precursor.
Preparation of the precursors and radiosynthesis of [
Two carbon-11-labeled radioligands were prepared through a standard methylation method, under the catalyzation of different bases, respectively. [ The B max of s 1 R in human brain was measured to be approximately 30-600 fmol/mg (3-60 nmol/L) 32, 33 . Thus, the radioligand with affinity of 0.6-12 nmol/L could be used for s 1 R imaging, and range of 0.3-6 nmol/L will be more suitable. The ex vivo s 1 R binding affinity of unlabeled HCC0923 (compound 13) and HCC0929 (compound 15) were measured through previously demonstrated methods (as described in Supporting Information) 28, 29 . The s 1 R binding affinities of 13 and 15 were 10.3 and 5.6 nmol/L, with the selectivities of 111.3-and 272.8-fold to s 2 R, respectively (Table 1 13,27 ). Compared to the most promising compound 6, both 13 and 15 showed a slight decrease of s 1 R binding affinity and selectivity, due to structure modifications necessary for radiolabeling; however, based on the criteria mentioned above, 13 and 15 still possessed suitable affinities for in vivo PET imaging of s 1 R.
Besides the binding affinity and selectivity to the target receptor, the logD is also another important parameter, especially for the radiotracer for brain imaging. The experimental logD PBS,pH7.4 AESD of compounds 13 and 15 were measured 34 to be 0.89AE0.06 and 1.73AE0.08, respectively.
Molecular docking studies of 6-hydroxypyridazinone derivatives
To predict the possible binding mode of the two radioligands, we performed molecular docking with Schrödinger Glide software (Schrödinger, LLC, New York, NY, USA) using the 2.5 Å resolution structure of the s 1 R bound to PD 144418, in a similar manner as reported previously 13, 14, 35 . Encouragingly, the top-ranked docked pose of PD 144418 in Fig. 2A (yellow) was nearly identical to that seen in the crystal structure ( Fig. 2A, cyan) , and the Glide score was comparable to Compd. what has been reported previously for high-affinity s 1 R ligands 13, 14, 35 . The reference compound 6, along with 13 and 15, was docked in the same way. All three compounds adopted similar conformations in the ligand-binding site as PD 144418, with good Glide Scores ( Table 2) . Like all ligands co-crystallized with the receptor to date, the poses for compounds 6, 13, and 15 featured an electrostatic interaction between the positively charged nitrogen in the ligand and E172 (Table 2 , Fig. 2B-D) . Additionally, as reported for all currently co-crystallized s 1 R antagonists 13, 14 , the primary hydrophobic regions of these compounds were positioned near Y203, pointing towards the membrane, and the secondary hydrophobic regions were pointing towards the bottom of the ligand binding site past D126. These results suggest that these compounds likely bind the receptor similarly to other high-affinity s 1 R ligands.
In vivo PET-CT imaging with [
11 C]HCC0923 in mice 36, 37 Following the encouraging data in ex vivo s 1 R binding assays and molecular docking, two radioligands, [ 11 C]HCC0923 and [ 11 C]HCC0929, were a step forward to further in vivo investigation.
We firstly assessed [ 11 C]HCC0923 in vivo conducting dynamic PET imaging focused on mice brains. In PET-CT studies, [ 11 C]HCC0923 exerted high BBB penetration and fast uptake when administered by intravenous bolus injection (100-150 mCi per animal), as shown in Fig. 3 . Based on a whole-brain analysis, the concentration of [ 11 C] HCC0923 in the mice brain reached a maximum uptake of 6.48% ID/cc within the first few minutes after injection, and sustained binding over the scanning time (60 min).
To investigate the specificity of [ 11 C]HCC0923, we performed PET imaging studies in mice with a 5-min pretreatment of compound 13 (unlabeled HCC0923) at different doses (1.25 and 12.5 mg/kg). Compared with the non-pretreat control (baseline, Fig. 3A ), we found that the [ 11 C]HCC0923 binding in mice brain was blocked in a dose-dependent manner with a stepwise reduction in the percent tracer uptake after administration of 13 ( Fig. 3B  and C) . At 1.25 mg/kg, we found an approximate 38% reduction in binding, estimated as the percent change in whole-brain radioactivity between peak uptake at 10 min and the lowest uptake at 60 min. Increasing the dose of 13 to 12.5 mg/kg resulted in a w54% reduction in [ 11 C]HCC0923 brain uptake, a dosedependent response to self-blockade and w45% of uptake attributed to non-specific binding. We observed a similar blockade level at the last 10 min, indicating saturation at 1.25 mg/kg. This finding demonstrates a high specific binding of [ 11 C]HCC0923 for s 1 R, with a dose-dependent response to self-blockade. (Fig. 4D) , which represents a dose-dependent response to selfblockade and w40% of uptake attributed to non-specific binding. The mice in vivo PET-CT studies demonstrated a high uptake and good mice brain clearance kinetic of [ 11 C]HCC0929 for s 1 R imaging in brain, with a dose-dependent response to selfblockade.
2.7.
Positive ligands blocking study of in vivo PET-CT imaging using [ 11 
C]HCC0929 in mice
To further validate the selectivity of s 1 R of the candidate radioligand [ 11 C]HCC0929, two highly s 1 R selective ligands, SA 4503 (s 1 R agonist) and PD 144418 (s 1 R antagonist) were adopted for positive ligands blocking study 36, 37 . Through the in vivo PET-CT imaging in mice brain (Fig. 5) , we found that administration of SA 4503 (2.75 mg/kg) or PD 144418 (2.99 mg/kg) could remarkably reduce the [ 11 C] HCC0929 binding in the mice brain by approximately 41% and 67%, respectively, measured as the percent change in whole radioactivity between peak uptake at w5 min and the lowest uptake at 60 min. The different blocking effects of two positive ligands might due to their entirely opposite functional profiles. The shape of time-active curve of self-blocking was close to the curve of PD 144418, since the compound 15 acted as the same as antagonist, but the binding affinity to s 1 R was a little higher than PD 144418.
In vivo biodistribution studies of [ 11 C]HCC0929 in mice
The biodistribution of radioligand [ 11 C]HCC0929 in mice was investigated by in vivo PET-CT imaging, and the data were acquired by using the FUSION module in PMOD (PMOD 4.003, PMOD Technologies Ltd., Zurich, Switzerland).
The analysis of detailed distribution of different brain regions of mice was obtained through the mouse (Ma-Benveniste-Mirrione) VOI atlas 38, 39 . Eight important functional regions of mice brain were selected: cortex, cerebellum, brain stem, thalamus, hypothalamus, striatum, hippocampus and amygdala. The radioligand [ 11 C] HCC0929 distributed in the selected brain regions were investigated and showed quite similar distribution patterns 40 without significant regional differences (Fig. 6) . In blocking studies, the uptake of [ 11 C] HCC0929 in different regions of mice brain was significantly decreased by co-injection of HCC0929. In high dose injection (2.88 mg/kg), all the selected brain regions of mice were decreased significantly as the same; while pretreated a low dose of HCC0929 (0.288 mg/kg), the cortex, striatum and hippocampus showed a moderate decrease compared to other mice brain regions, which were mainly because of the different express of s 1 R in these regions.
The distribution of major organs in mice was analyzed using the PBAS module in PMOD 4.003. The mean radioactive uptake in brain and major organs at each time point is showed in Fig. 7 . The highest uptake occurred at 5 min in brain (7.66AE0.82% ID/cc), heart (5.10AE0.68% ID/cc), lung (6.75AE0.86% ID/cc) and kidney (8.87AE1.16% ID/cc), and then the radioligand was gradually washed out from these organs. Whereas in liver and spleen, due to the accumulation of [ uptake was behind other organs. The uptake in liver peaked at 30 min at 14.70AE2.03% ID/cc and slightly decreased in 60 min; in spleen, the maximum radioactivity uptake reached in 15 min at 13.32AE2.03% ID/cc and then was slowly washed out during study.
Conclusions
In summary, two novel carbon-11 labeled s 1 R radioligands with a 6-hydroxypyridazinone scaffold, [ 11 C]HCC0923 and [ 11 C]HCC0929, were successfully prepared and evaluated in mice. Both two radioligands can highly bind to s 1 R in the mice brain, with good selectivity and specificity. Of the two novel 11 Clabeled sigma-1 receptor radioligands, [ 11 C]HCC0929 possessed better kinetic property and specificity which was further investigated in positive ligands blocking studies in mice PET-CT brain imaging, using classic s 1 R agonist SA 4503 and s 1 R antagonist PD 144418. Both s 1 R ligands could extensively decreased the uptake of [ 11 C]HCC0929 in mice brain, with different kinetic uptake and washout properties. Besides, the biodistribution of major brain regions and organs of mice were determined in vivo. The radioligand [ 11 C]HCC0929 distributed in the selected brain regions showed quite similar distribution patterns as reported, and the distribution in major organs extent the good pharmacokinetic properties in vivo. These results demonstrated its promise as preclinical tools for visualizing and quantitating s 1 R density in the mice brain in vivo.
Application [ 11 C]HCC0929 as PET probes could be used to quantify s 1 R expression in various neurological disorders, and would also be valuable for evaluation of potential drugs in living subjects. The approach is also valuable for expanding the variety and diversity of PET radiotracers for s 1 R imaging to meet the requirements for practical clinic application and therefore warrants further investigation.
Experimental
General methods and materials
All commercially available chemical reagents and solvents were of ACS-grade purity or higher, and used without further purification. 1 H NMR and 13 C NMR spectra data were recorded on a JEOL JNM-ECZ500R Spectrometer (JEOL Ltd, Tokyo, Japan) at 500 MHz ( 1 H) and 126 MHz ( 13 C) using chloroform-d. Chemical shifts were given in d values (ppm), using tetramethylsilane (TMS) as the internal standard; coupling constants (J) were given in Hz. Signal multiplicities were characterized as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad signal).
Analytical thin layer chromatography (TLC) was performed on silica gel GF254. Column chromatographic purification was carried out using silica gel. Analytical separation was conducted on an Agilent 1100 series HPLC (Agilent Technologies, Inc., Santa Clara, CA, USA) fitted with a diode-array detector, quaternary pump, vacuum degasser, and autosampler. Mass spectrometry data were recorded on an Agilent 6310 ion trap mass spectrometer (ESI source, Agilent Technologies, Inc., Santa Clara, CA, USA) connected to an Agilent 1200 series HPLC with quaternary pump, vacuum degasser, diode-array detector, and autosampler.
[ Micro PET-CT imaging was performed in anesthetized (isoflurane) mice (BALB/c) to minimize discomfort. Highly trained animal technicians monitored animal safety throughout all procedures, and veterinary staff were responsible for daily care. All mice were socially housed in cages appropriate for the physical and behavioral health of the individual animal and were given unlimited access to food and water, with additional nutritional supplements provided as prescribed by the attending veterinary staff.
Chemical synthesis
4.2.1. General procedure for the preparation of intermediates 9 and 10 6-Hydroxy-2-(4-methoxyphenyl)pyridazin-3(2H)-one (9) . To a mixture of (4-methoxyphenyl)hydrazine hydrochloride (7, 55 mmol) and maleic anhydride (50 mmol) in H 2 O (400 mL), concentrated hydrochloric acid solution (40 mL) was added slowly with stirring. The mixture was heated at 120 C for 8 h. The progress of the reaction was monitored by TLC. After cooling to room temperature and filtrating, the resulting solid was washed with ice-water and dissolved in a saturated sodium bicarbonate solution. After another filtration, the resulting filtrate was neutralized with 1 mol/L hydrochloric acid and formed a precipitate. The precipitate was then filtered and washed with water to yield 6-hydroxy-2-(4-methoxyphenyl)pyridazin-3(2H )-one, 9, as a white solid (7.22 g, 66.2%). 1 
2-(3,4-Dichlorophenyl)-6-hydroxypyridazin-3(2H)-one (10).
The procedure described for the synthesis of 9 was applied to the initial compound 8 (55 mmol), maleic anhydride (50 mmol), and H 2 O (400 mL) with concentrated HCl solution (40 mL) to afford 2-(3,4-dichlorophenyl)-6-hydroxypyridazin-3(2H )-one, 10 as a white solid (9.01 g, 70.1%). 
4.2.2.
General procedure for the preparation of intermediates 11 and 12 6-(3-Bromopropoxy)-2-(4-methoxyphenyl)pyridazin-3(2H)-one (11) .
To a solution of 9 (10 mmol) and 1,3-dibromopropane (20 mmol) in acetone (100 mL), potassium carbonate (20 mmol) was added and the mixture was refluxed for 4 h. The progress of the reaction was monitored by TLC. After cooled to room temperature, the mixture was filtered and the solvent was evaporated under reduced pressure. The crude product was purified by means of flash chromatography (hexane/ethyl acetateZ50/1) to yield 6-(3-bromopropoxy)-2-(4-methoxyphenyl)pyridazin-3(2H)-one, 11, as a pale-yellow oil (1.89 g, 55.6% 6-(3-Bromopropoxy)-2-(3,4-dichlorophenyl)pyridazin-3(2H)-one (12). The procedure described for the synthesis of 11 was applied to intermediate 10 (10 mmol), 1,3-dibromopropane (20 mmol), and potassium carbonate (20 mmol) in acetone (100 mL) to afford 6-(3-bromopropoxy)-2-(3,4-dichlorophenyl)pyridazin-3(2H )-one, 12 as a light yellow oil (1.97 g, 52.0%). 
4.2.3.
General procedure for the preparation of compounds 13 to 15 2-(4-Methoxyphenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H)-one (13) . A mixture of intermediate 11 (5 mmol) and piperidine (5.5 mmol) in acetonitrile (50 mL) and cesium carbonate (10 mmol) was heated and refluxed for 2 h. After filtering, the resulting filtrate was evaporated to dryness under reduced pressure. The residue was suspended in water (50 mL) and extracted with dichloromethane (3 Â 25 mL). The combined organic layers were dried with anhydrous magnesium sulfate, the filtrate was evaporated under reduced pressure, and the crude product was purified by means of flash chromatography (CH 2 Cl 2 / CH 3 OHZ10/1) to yield 2-(4-methoxyphenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H )-one, 13, as a yellow oil (1.46 g, 84.8%). 1 tert-Butyl 4-(3-((1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-propyl)piperazine-1-carboxylate (14) . The procedure described for the synthesis of 13 was applied to intermediate 12 (5 mmol), tert-butyl piperazine-1-carboxylate (5.5 mmol), and cesium carbonate (10 mmol) in acetonitrile (50 mL) to afford 4-(3-((1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-propyl) piperazine-1-carboxylate, 14 as a light yellow oil (1.78 g, 73.5%). 1 2-(4-Hydroxyphenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H)-one (16, precursor P1) Under N 2 , a solution of 13 (1 mmol) in dichloromethane (14 mL) was kept in an acetone-dry ice bath at -78 C. 6 mL of Boron tribromide solution (1.0 mol/L in dichloromethane) was added carefully to the stirring solution and kept at -78 C for 2 h. As the solution of boron tribromide was added, a pale yellow precipitate formed. The reaction mixture was gradually warmed to room temperature and kept stirring overnight. The reaction mixture was then hydrolyzed by careful shaking with 40 mL of H 2 O, thus precipitating a white solid, which was dissolved by the addition of 30 mL of dichloromethane. The organic layer was separated and extracted with 20 mL of 2 mol/L sodium hydroxide; the alkaline extract was neutralized with dilute hydrochloric acid and extracted with dichloromethane (3 Â 10 mL). The combined organic layers were dried with anhydrous magnesium sulfate, the filtrate was evaporated under reduced pressure, and the crude product was purified by means of flash chromatography (CH 2 Cl 2 /CH 3 OHZ10/1) to yield 2-(4-hydroxyphenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H)-one (16, C. 2 mL of hydrogen chloride solution (1.0 mol/L in diethyl ether) was added to the stirring solution. As the solution of hydrogen chloride was added, a pale yellow precipitate was formed. The reaction mixture was gradually warmed to room temperature and kept stirring overnight. After that, the reaction mixture was neutralized by 30 mL of saturated sodium bicarbonate solution and extracted with dichloromethane (3 Â 10 mL). The combined organic layers were dried with anhydrous magnesium sulfate, the filtrate was evaporated under reduced pressure, and the crude product was purified by means of flash chromatography (CH 2 Cl 2 /CH 3 OHZ10/1) to yield 2-(3,4-dichlorophenyl)-6-(3-(piperazin-1-yl)propoxy)pyridazin-3(2H)-one (17, ) was trapped in a TRACERlab FX-M synthesizer reactor (General Electric) preloaded with a solution of precursor P1 in anhydrous DMF (2.0 mg/mL, 0.3 mL) and NaOH (8 mg). The solution was stirred at 120 C for 3 min, and 0.1% trifluoroacetic acid (TFA) in water (1.2 mL) was added. The reaction mixture was purified by reverse phase semipreparative HPLC (Agilent Eclipse XDB-C18, 5 mm, 250 mm Â 9.4 mm, flow rateZ5.0 mL/min, mobile phaseZ0.1% TFA in water/0.1% TFA in acetonitrile, 82/18, v/v), and the desired fraction was collected. The final product was reformulated by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H 2 0 (5 mL), eluting with DMSO (1 mL), and diluting with saline solution (0.9%, 9 mL).
The average time required for the synthesis from end of cyclotron bombardment to end of synthesis was approximate 40-50 min. The average radiochemical yield was 6%À15% (nondecay corrected to trapped [ 11 C]CH 3 I). Chemical and radiochemical purities were !95% with a specific activity 1.29AE0.2 Ci/mmol (EOB). C for 3 min, and 0.1 mol/L ammonium formate (AF) in water (1.2 mL) was added. The reaction mixture was purified by reverse phase semipreparative HPLC (Phenomenex Luna 5u C8(2), 250 mm Â 10 mm, 5 mm, flow rateZ5.0 mL/min, mobile phaseZ0.1 mol/L AF in water/acetonitrile, 65/35, v/v), and the desired fraction was collected. The final product was reformulated by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H 2 0 (5 mL), eluting with EtOH (1 mL), and diluting with saline solution (0.9%, 9 mL).
The average time required for the synthesis from end of cyclotron bombardment to end of synthesis was approximate 40-50 min. The average radiochemical yield was 3%À8% (nondecay corrected to trapped [ 11 C]CH 3 I). Chemical and radiochemical purities were !95% with a specific activity 1.62AE0.2 Ci/mmol (EOB).
Molecular docking
Molecular docking into the s 1 R was performed in the manner of previous work 13, 14, 35 with Glide 5.5 extra precision (XP) Maestro 11 Schrodinger software (Schrödinger, LLC, New York, NY, USA) release 2016e3 41 . The 2.5 Å resolution structure of s 1 R in complex with PD 144418 (PDB 5KH1) was used for docking, compared with the ex vivo binding affinity 42 . Because the structure has three protomers in the asymmetric unit, only chain C was used for docking studies. Lipids, ions, and waters were removed before protein preparation, thus leaving only the protein and ligand. Hydrogen atoms were added, and the protein was further refined by assignment of hydrogen bonds and minimization of energy for the OPLS3 force field. The grid used for docking was centered on the location of the co-crystallized ligand PD 144418, and was 20 Å in the x, y, and z dimensions. Poses were ranked according to glide score and inspected visually. Only poses in which the ligand's basic amine made an electrostatic interaction with E172 were considered plausible, as this has been observed in all five existing s 1 R crystal structures currently available 13, 14 .
Mice PET-CT acquisition and post processing
Male Balb/c mice were tested in groups, each group contained 4 mice, anesthetized with inhalational isoflurane (Patterson Vet Supply, Inc., Greeley, CO, USA) at 2% in a carrier of 2 L/min medial oxygen, and maintained at 1% isoflurane for the duration of the scan. The mice were arranged side-by-side in two layers in a Triumph Trimodality PET/CT/SPECT scanner (Gamma Medica, Northridge, CA, USA). Mice were injected standard references or vehicle via a lateral tail vein catheterization at the start of PET acquisition. Dynamic PET acquisition lasted for 60 min followed by computed tomography (CT) for anatomic coregistration. PET data were reconstructed using a 3D-MLEM method resulting in a full width at half-maximum resolution of 1 mm. Reconstructed images were exported from the scanner in DICOM format along with an anatomic CT for rodent studies. These files were imported and analyzed using AMIDE (a medical imaging data examiner) software (an open-source software, Los Angeles, CA, USA) 43 and PMOD (PMOD4.003, PMOD Technologies Ltd., Zurich, Switzerland).
Mice PET-CT image analysis
Volumes of interest (VOIs) were generated manually in forms of spheres under the guide of high-resolution CT structural images and summed PET data in mice brain regions, with a radius no less than 1 mm to minimize partial volume effects. Time-activity curves (TACs) were exported as decay-corrected activity per unit volume. The TACs were expressed as percent injected dose per unit volume for analysis.
